75.15
전일 마감가:
$74.06
열려 있는:
$73.83
하루 거래량:
1.60M
Relative Volume:
0.70
시가총액:
$14.48B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-31.18
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
+2.05%
1개월 성능:
+13.49%
6개월 성능:
+89.53%
1년 성능:
+171.59%
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
BBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
BBIO
Bridgebio Pharma Inc
|
75.15 | 14.27B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-11 | 개시 | Bernstein | Outperform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
Castleark Management LLC Cuts Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Gilder Gagnon Howe & Co. LLC Boosts Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Eventide Asset Management LLC Decreases Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Oncology Therapeutics: Promising KRAS Drug DeveloperIn My View, At Least - Seeking Alpha
BridgeBio Pharma stock hits all-time high at 75.13 USD - Investing.com
BridgeBio Pharma stock hits all-time high at 75.13 USD By Investing.com - Investing.com Australia
BridgeBio Pharma (BBIO) Valuation After Attruby-Driven Earnings Beat and Renewed Analyst Support - Yahoo Finance
What Recent Clinical Wins Mean For BridgeBio Pharma’s Evolving Growth Story - Yahoo Finance
Frontier Capital Management Co. LLC Sells 233,538 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Bernstein initiates BridgeBio Pharma stock coverage with Outperform rating By Investing.com - Investing.com Canada
Bernstein Initiates BridgeBio Pharma at Outperform With $94 Price Target - marketscreener.com
This Option Care Health Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday - Benzinga
HighVista Strategies LLC Increases Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Bernstein Initiates Coverage of BridgeBio Pharma (BBIO) with Outperform Recommendation - Nasdaq
BBIO Gets "Outperform" Rating as Bernstein Initiates Coverage | - GuruFocus
Federated Hermes Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio (BBIO) Unveils Promising Preclinical Data for Cancer T - GuruFocus
BridgeBio (BBIO) Unveils Promising Preclinical Data for Cancer Treatment - GuruFocus
Apuli Maricel, chief accounting officer, sells $148k in BridgeBio (BBIO) - Investing.com Canada
This Hot Biotech Stock Just Set New All-Time Highs - Barchart.com
BridgeBio Pharma (NASDAQ:BBIO) CAO Sells $148,520.00 in Stock - MarketBeat
Insider Sell Alert: Maricel Apuli Sells 2,000 Shares of BridgeBi - GuruFocus
Stempoint Capital LP Reduces Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Invesco Ltd. Has $120.95 Million Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
89,312 Shares in BridgeBio Pharma, Inc. $BBIO Acquired by WINTON GROUP Ltd - MarketBeat
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 40,000 Shares of Stock - MarketBeat
BridgeBio Pharma CEO Kumar sells $5.9 million in BBIO stock By Investing.com - Investing.com Canada
Bridgebio Pharma Insider Sold Shares Worth $5,908,476, According to a Recent SEC Filing - marketscreener.com
BridgeBio Pharma (NASDAQ:BBIO) Hits New 12-Month HighTime to Buy? - MarketBeat
Price-Driven Insight from (BBIO) for Rule-Based Strategy - news.stocktradersdaily.com
BridgeBio Pharma, Inc. $BBIO Holdings Lifted by Bosun Asset Management LLC - MarketBeat
Tema Etfs LLC Sells 25,530 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Edgestream Partners L.P. Makes New $1.92 Million Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. $BBIO Position Cut by Affinity Asset Advisors LLC - MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Norges Bank Purchases New Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Lymphatic Malformations Market Expected to Experience Major - openPR.com
Legal & General Group Plc Purchases 23,716 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Panagora Asset Management Inc. Boosts Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
72,047 Shares in BridgeBio Pharma, Inc. $BBIO Acquired by Capital Fund Management S.A. - MarketBeat
Rhumbline Advisers Grows Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
How BridgeBio Pharma Inc. stock valuations compare to rivalsMarket Activity Recap & Free Fast Gain Swing Trade Alerts - Newser
BridgeBio Pharma stock hits 52-week high at $72.36 By Investing.com - Investing.com South Africa
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week HighWhat's Next? - MarketBeat
BridgeBio Pharma stock hits 52-week high at $72.36 - Investing.com
What valuation multiples suggest for BridgeBio Pharma Inc. stockJuly 2025 EndofMonth & Accurate Entry and Exit Point Alerts - Newser
Prudential Financial Inc. Has $5.07 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
What dividend safety score for BridgeBio Pharma Inc. stockJuly 2025 Reactions & High Yield Stock Recommendations - Newser
BridgeBio Pharma Surges 170% as New Clinical Partnerships Spark Valuation Debate - Yahoo Finance
Is BridgeBio Pharma Inc. (2CL) stock cheap by valuation metricsJuly 2025 Snapshot & Consistent Income Trade Recommendations - Newser
Can BridgeBio Pharma Inc. (2CL) stock ride next bull market cycleJuly 2025 PreEarnings & Accurate Intraday Trade Tips - Newser
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bridgebio Pharma Inc 주식 (BBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Dec 04 '25 |
Sale |
74.40 |
40,000 |
2,975,913 |
775,686 |
| Kumar Neil | Chief Executive Officer |
Dec 05 '25 |
Sale |
73.31 |
40,000 |
2,932,563 |
755,686 |
| Kumar Neil | Chief Executive Officer |
Nov 20 '25 |
Sale |
65.84 |
26,156 |
1,722,224 |
228,776 |
자본화:
|
볼륨(24시간):